期刊文献+

噻托溴铵联合小剂量阿奇霉素对慢性阻塞性肺疾病的疗效观察 被引量:3

原文传递
导出
摘要 目的观察噻托溴铵联合小剂量阿奇霉素对稳定期慢性阻塞性肺疾病(COPD)的疗效和安全性。方法选取已经确诊的120例COPD患者,采取随机对照的研究方法,分为对照组、噻托溴铵组、阿奇霉素组及联合组,每组30例。对照组给予常规治疗;噻托溴铵组给予噻托溴铵吸入剂18μg,每晚睡前吸入;阿奇霉素组给予阿奇霉素片250 mg,隔日1次口服;联合组给予噻托溴铵吸入和阿奇霉素口服,用法用量同噻托溴铵组和阿奇霉素组;疗程均为1年。观察治疗前和治疗后患者的肺功能、运动耐量、生活质量、COPD急性加重次数。结果对照组:肺功能、运动耐量、生活质量明显改善,COPD急性加重次数等各项观察指标治疗前后无明显变化;噻托溴铵、阿奇霉素及联合组:各项观察指标较治疗前明显改善(P<0.05),联合组各项观察指标优于噻托溴铵和阿奇霉素组(P<0.05)。结论噻托溴铵联合小剂量阿奇霉素能够更好改善稳定期COPD患者的肺功能、生活质量,使患者运动耐量增加,临床疗效提高,安全性好,优于单药治疗。
出处 《临床医学》 CAS 2016年第10期56-58,共3页 Clinical Medicine
  • 相关文献

参考文献6

  • 1蔡柏蔷.慢性阻塞性肺疾病诊断、处理和预防全球策略(2011年修订版)解读[J].中华结核和呼吸杂志,2012,35(4):249-256. 被引量:156
  • 2Tashkin DP, Celli B, Senn S, et al. 4-year trial of tiotropium in chron- ic obstructive puhnonary disease[J]. N Engl J Med,2008, 359(15) : 1543 - 1554.
  • 3I)al Negro RW, Bonadiman L, Bonadiman L, et al. Changes of clini- cal outcomes and health care resources in moderate and in severe COPD treated uniquely with tiotropium 18 mcg od for twenty-fourmonths[J]. Pulm Pharmacol Ther,2011,24(4) :373 -376.
  • 4Cmsbie PA, Woodhead MA. Long-term macrolide therapy in chronic in- flammatory airway diseases [ J ]. Eur Respir J,2009,33 ( 1 ) : 171 - 181.
  • 5郭锋,况九龙.超氧化物歧化酶基因多态性及其活力与慢性阻塞性肺疾病的易感性研究[J].中华结核和呼吸杂志,2011,34(6):424-428. 被引量:17
  • 6Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithro- mycin therapy [ J ]. Am J Respir Crit Care Med, 2014, 189(12) : 1503 - 1508.

二级参考文献11

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8233
  • 2Young RP,Hopkins R,Black PN,et al.Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function.Thorax,2006,61:394-399.
  • 3Wang LI,Miller DP,Sai Y,et al.Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk.J Natl Cancer Inst,2001,93:1818-1821.
  • 4Siedlinski M,van Diemen CC,Postma DS,et al.Superoxide dismutases,lung function and bronchial responsiveness in a general population.Eur Respir J,2009,33:986-992.
  • 5von Ahsen N,Oellerich M.The intronic prothrombin 19911A》G polymorphism influences splicing efficiency and modulates effects of the 20210G》A polymorphism on mRNA amount and expression in a stable reporter gene assay system.Blood,2004,103:586-593.
  • 6Shao J,Chen L,Marrs B,et al.SOD2 polymorphisms:unmasking the effect of polymorphism on splicing.BMC Med Genet,2007,8:7.
  • 7Dahl M,Bowler RP,Juul K,et al.Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations.Am J Respir Crit Care Med,2008,178:906-912.
  • 8Hanta I,Kocabas A,Canacankatan N,et al.Oxidant-antioxidant balance in patients with COPD.Lung,2006,184:51-55.
  • 9Daga MK,Chhabra R,Sharma B,et al.Effects of exogenous vitamin E supplementation on the levels of oxidants and antioxidants in chronic obstructive pulmonary disease.J Biosci,2003,28:7-11.
  • 10GOLD Executive Committee. Global strategy for the diagnosis,management,and prevention of chronic obstrnctive pulmonary disease (Revised 2011)[EB/OL].http://www.goldcopd.com,2012.

共引文献166

同被引文献14

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部